Cancer remains a major global public health challenge, driven by high rates of morbidity and mortality and necessitating a shift toward precise and personalized care. Traditional cancer management, encompassing standard imaging and systemic therapies, often suffers from limitations such as restricted sensitivity, poor real-time monitoring, lack of tumor selectivity, and systemic toxicity. Theranostics has emerged as a transformative strategy by integrating molecular diagnostics and targeted therapy into a unified platform, enabling the visualization of tumor-specific biomarkers, guiding patient selection, delivering therapeutic agents with high specificity, and monitoring treatment response instantaneously. This review comprehensively explains the fundamental principles of theranostics, detailing the core technology that lies in developing dual-functional agents, including radiolabeled compounds and multifunctional nanotheranostics (such as liposomes and activatable molecular agents). These agents leverage imaging modalities such as positron emission tomography, single-photon emission computed tomography, magnetic resonance imaging, and photoacoustic imaging to precisely guide therapeutic interventions like radioligand therapy, photothermal therapy, and photodynamic therapy. Ongoing advances in these integrated systems promise to refine biodistribution, minimize off-target harm, and improve clinical outcomes, fundamentally altering future strategies for individualized cancer management.